Novartis AG logo

Novartis AG

NVS
Healthcare|Drug Manufacturers - General|Switzerland
$152.84
+0.00 (+0.00%)
DCF (FCF)
$89.99
Earnings Power
$56.11

Upcoming Data Readouts (38)

Jun 2026
Est. completion
P1Acute Lymphoblastic Leukemia
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Jul 2026
Est. completion
P1Multiple Myeloma
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Aug 2026
Est. completion
P4Ankylosing Spondylitis (AS)
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Sep 2026
Est. completion
Metastatic Non-small Cell Lung Cancer (NSCLC)
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
NCT02622581n=12,400
Sep 2026
Est. completion
Hidradenitis Suppurativa
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.
Oct 2026
Est. completion
Primary Hypercholesterolemia
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Oct 2026
Est. completion
Solid Tumours in Advanced Stages
National Register of Actionable Mutations
Oct 2026
Est. completion
Non-Small-Cell Lung Carcinoma
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Nov 2026
Est. completion
P4Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
Dec 2026
Est. completion
Multiple Sclerosis
DreaMS - Validation Study 1
Dec 2026
Est. completion
P1Breast Cancer
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Jan 2027
Est. completion
P3Breast Cancer
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Feb 2027
Est. completion
P2Melanoma
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Feb 2027
Est. completion
P3Chronic Spontaneous Urticaria (CSU)
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Feb 2027
Est. completion
P2Advanced Breast Cancer
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Feb 2027
Est. completion
P1Mycosis Fungoides
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Mar 2027
Est. completion
P3B-cell Acute Lymphoblastic Leukemia
Study of Out of Specification for Tisagenlecleucel
Apr 2027
Est. completion
P1ALK-positive NSCLC
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
Apr 2027
Est. completion
Paroxysmal Nocturnal Hemoglobinuria
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
Jul 2027
Est. completion
P3Ovarian Neoplasm Epithelial
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Awaiting Results (15)

Trials past primary completion date but still active — data readout may be imminent.

Mar 2026
P3
Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
NCT06267560
Mar 2026
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
NCT07465679
Mar 2026
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
NCT06053749
Feb 2026
Development of Novel Clinical Endpoints in Intermediate AMD
NCT03349801
Dec 2025
P1
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
NCT06430671
Oct 2025
P1P2
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
NCT03945318
Jul 2025
P4
Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema
NCT06498050
Jan 2025
P3
Detect V / CHEVENDO (Chemo vs. Endo)
NCT02344472
Sep 2024
P2
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
NCT01990196
Jul 2023
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
NCT04497285

Recent Press Releases